Edition:
India

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

62.59USD
1:32am IST
Change (% chg)

$-0.30 (-0.48%)
Prev Close
$62.89
Open
$62.90
Day's High
$62.91
Day's Low
$62.33
Volume
1,506,201
Avg. Vol
3,409,059
52-wk High
$66.41
52-wk Low
$52.83

Latest Key Developments (Source: Significant Developments)

Viralytics Says Federal Court Of Australia Approved Scheme Of Arrangement
Monday, 4 Jun 2018 

June 4 (Reuters) - Viralytics Ltd ::FEDERAL COURT OF AUSTRALIA APPROVES SCHEME OF ARRANGEMENT.SCHEME, UPON IMPLEMENTATION, WILL RESULT IN MERCK SHARP & DOHME (HOLDINGS) PTY BUYING ALL SHARES IN CO.  Full Article

Oncosec Expands Relationship With Merck For Combination Of Immunopulse Il-12 And Keytruda
Tuesday, 8 May 2018 

May 8 (Reuters) - OncoSec Medical Inc ::ONCOSEC EXPANDS RELATIONSHIP WITH MERCK, ANNOUNCES CLINICAL COLLABORATION TO EVALUATE COMBINATION OF IMMUNOPULSE IL-12 AND KEYTRUDA FOR TRIPLE NEGATIVE BREAST CANCER.ONCOSEC MEDICAL - PLANNED TRIAL WILL EVALUATE SAFETY, EFFICACY OF COMBINATION IN CERTAIN PATIENTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC TNBC.ONCOSEC MEDICAL SAYS UNDER COLLABORATION AGREEMENT, ONCOSEC WILL SPONSOR, FUND STUDY AND MERCK WILL PROVIDE KEYTRUDA.ONCOSEC MEDICAL SAYS ADDITIONAL DETAILS OF THE COLLABORATION WERE NOT DISCLOSED.  Full Article

Keytruda Monotherapy Met Primary Endpoint In Phase 3 Study, Significantly Improving OS As First-Line Therapy In Locally Advanced Or Metastatic NSCLC Patients Expressing PD-L1 In At Least 1 Pct O
Monday, 9 Apr 2018 

April 9 (Reuters) - Merck & Co Inc ::KEYTRUDA® (PEMBROLIZUMAB) MONOTHERAPY MET PRIMARY ENDPOINT IN PHASE 3 KEYNOTE-042 STUDY, SIGNIFICANTLY IMPROVING OS AS FIRST-LINE THERAPY IN LOCALLY ADVANCED OR METASTATIC NSCLC PATIENTS EXPRESSING PD-L1 IN AT LEAST 1 PERCENT OF TUMOR CELLS.SAFETY PROFILE OF KEYTRUDA IN PHASE 3 TRIAL WAS CONSISTENT.PHASE 3 KEYNOTE-042 TRIAL WILL CONTINUE TO EVALUATE PROGRESSION-FREE SURVIVAL (PFS), WHICH IS A SECONDARY ENDPOINT.  Full Article

Incyte, Merck Provide Update On Phase 3 Study
Friday, 6 Apr 2018 

April 6 (Reuters) - Incyte Corp ::INCYTE AND MERCK PROVIDE UPDATE ON PHASE 3 STUDY OF EPACADOSTAT IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) IN PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA.INCYTE AND MERCK PROVIDE UPDATE ON PHASE 3 STUDY OF EPACADOSTAT IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) IN PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA.STUDY'S SECOND PRIMARY ENDPOINT OF OVERALL SURVIVAL ALSO IS NOT EXPECTED TO REACH STATISTICAL SIGNIFICANCE.BASED ON RESULTS, AND AT RECOMMENDATION OF EDMC, PHASE 3 STUDY WILL BE STOPPED.252 WAS CONSISTENT WITH THAT OBSERVED IN STUDIES OF EPACADOSTAT IN COMBINATION WITH KEYTRUDA.252 STUDY EVALUATING EPACADOSTAT WITH KEYTRUDA DETERMINED STUDY DID NOT MEET PRIMARY ENDPOINT.  Full Article

Merck Receives Fast-Track Designation For Tepotinib In Non-Small Cell Lung Cancer In Japan
Tuesday, 27 Mar 2018 

March 27 (Reuters) - Merck & Co Inc ::MERCK RECEIVES FAST-TRACK DESIGNATION FOR TEPOTINIB IN NON-SMALL CELL LUNG CANCER IN JAPAN.MERCK & CO INC - ‍SAKIGAKE DESIGNATION ENCOMPASSES POSSIBILITY FOR A TARGET REVIEW PERIOD OF 6 MONTHS​.MERCK & CO INC - ‍JAPANESE MINISTRY OF HEALTH, LABOUR AND WELFARE GRANTS SAKIGAKE DESIGNATION FOR TEPOTINIB​.  Full Article

GE Appoints Michael Holston As General Counsel
Friday, 23 Feb 2018 

Feb 23 (Reuters) - General Electric Co ::SAYS MICHAEL HOLSTON NAMED SENIOR VICE PRESIDENT AND GENERAL COUNSEL OF GE‍​.SAYS HOLSTON JOINS GE FROM MERCK.SAYS HOLSTON SUCCEEDS ALEX DIMITRIEF.  Full Article

Merck And Viralytics Announce Acquisition Agreement
Wednesday, 21 Feb 2018 

Feb 21 (Reuters) - Merck & Co Inc ::MERCK AND VIRALYTICS ANNOUNCE ACQUISITION AGREEMENT, EXPANDING MERCK'S LEADING IMMUNO-ONCOLOGY PIPELINE.MERCK - PROPOSED ACQUISITION VALUES THE TOTAL ISSUED SHARES IN VIRALYTICS AT APPROXIMATELY AUD 502 MILLION (USD 394 MILLION).MERCK - ON COMPLETION OF TRANSACTION, VIRALYTICS WILL BECOME A WHOLLY-OWNED SUBSIDIARY OF MERCK.  Full Article

Merck Says Its Selumetinib Granted Orphan Drug Designation By FDA For Neurofibromatosis Type 1
Thursday, 15 Feb 2018 

Feb 15 (Reuters) - Merck & Co Inc ::SELUMETINIB GRANTED ORPHAN DRUG DESIGNATION BY THE U.S. FDA FOR NEUROFIBROMATOSIS TYPE 1.MERCK & CO INC - ‍FDA GRANTED ORPHAN DRUG DESIGNATION FOR SELUMETINIB, A MEK 1/2 INHIBITOR, FOR TREATMENT OF NEUROFIBROMATOSIS TYPE 1​.MERCK & CO INC - PHASE II TRIAL RESULTS FOR SELUMETINIB ARE EXPECTED LATER IN 2018.  Full Article

Affimed Reports New Data For AFM13 From Two Separate Clinical Trials
Thursday, 1 Feb 2018 

Feb 1 (Reuters) - Affimed Nv ::AFFIMED REPORTS NEW DATA FOR AFM13 FROM TWO SEPARATE CLINICAL TRIALS IN HODGKIN AND CD30-POSITIVE LYMPHOMAS.AFFIMED NV - ‍DATA DEMONSTRATE THAT AFM13 WAS WELL-TOLERATED​.AFFIMED NV - ‍DATA DEMONSTRATE AFM13 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) DOUBLED COMPLETE RESPONSE RATE IN HODGKIN LYMPHOMA PATIENTS​.AFFIMED NV - ‍EARLY DATA SUGGEST NEW OPPORTUNITY FOR AFM13 IN CD30-POSITIVE LYMPHOMA​.AFFIMED NV - ‍AFM13 IS CLINICALLY ACTIVE AND WELL-TOLERATED AS MONO- AND COMBINATION THERAPY​.AFFIMED NV - ‍ AFM13 IN COMBINATION WITH KEYTRUDA WAS WELL-TOLERATED WITH MOST OF ADVERSE EVENTS OBSERVED MILD TO MODERATE IN NATURE.  Full Article

PharmAbcine Enters in Collaboration With MSD
Thursday, 1 Feb 2018 

Feb 1 (Reuters) - Merck & Co Inc ::PHARMABCINE ENTERS COLLABORATION WITH MSD FOCUSED ON CLINICAL EVALUATION OF TTAC-0001 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) IN RECURRENT GLIOBLASTOMA AND BREAST CANCER.PHARMABCINE SAYS WILL CONDUCT INTERNATIONAL PHASE I/II STUDIES TO EVALUATE POTENTIAL CLINICAL SYNERGY OF COMBINING TTAC-0001 WITH KEYTRUDA.PHARMABCINE INC SAYS HAS ENTERED INTO A COLLABORATIVE AGREEMENT WITH MSD.  Full Article

Photo

U.S. Supreme Court to hear Merck appeal over Fosamax suits

WASHINGTON The U.S. Supreme Court on Thursday agreed to hear Merck & Co's appeal of a lower court's ruling that revived hundreds of lawsuits accusing the company of failing to adequately warn patients of the risks of thigh bone fractures associated with its osteoporosis drug Fosamax.